SCHEMBL17184635

SCHEMBL17184635

COC(=O)c1cc(F)c(C)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
CNR2 P34972 1/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
POLB P06746 3/20 0.48
KDM4E B2RXH2 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
GAA P10253 1/20 0.48
NFKB1 P19838 1/20 0.48
XDH P47989 1/20 0.48
GFER P55789 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
FUT7 Q11130 1/20 0.48
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114318 0.87 KMT2A (0.61) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL18306466 0.87 HDAC1 (0.59) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL18031512 0.84 HTT (0.61) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL17894021 0.82 LMNA (0.58) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL14077650 0.81 KDM4E (0.52) LMNAALDH1A1L3MBTL1CNR2POLB
SCHEMBL18969524 0.81 KMT2A (0.51) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL6066809 0.80 CNR2 (0.62) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL29555188 0.80 KDM4E (0.66) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL20703659 0.80 KDM4E (0.50) LMNAALDH1A1L3MBTL1CNR2KMT2A
SCHEMBL2671419 0.80 KDM4E (0.66) LMNAALDH1A1L3MBTL1CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
CN-116348464-A Benzimidazolone GLP-1 receptor agonists and uses thereof 杭州中美华东制药有限公司 2023-06-27 CN disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
US-20160244460-A1 ANTIVIRAL COMPOUNDS Janssen Pharmaceuticals, Inc. 2016-08-25 US disclosed
WO-2015161014-A1 HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR LMNA 3704/4885ALDH1A1 2478/4885L3MBTL1 2314/4885
US-20160244460-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 LMNA 2978/4885ALDH1A1 4011/4885L3MBTL1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.